Outcomes of Treatment and Factors Influencing Prognosis in Ugandan Children with Acute Myeloid Leukaemia - Report - MDSpire

Outcomes of Treatment and Factors Influencing Prognosis in Ugandan Children with Acute Myeloid Leukaemia

  • By

  • Richard Nyeko

  • Mariana Kruger

  • Nixon Niyonzima

  • Barnabas Atwiine

  • Jennifer Zungu

  • Joyce Balagadde Kambugu

  • Stijn Verhulst

  • Jaques van Heerden

  • December 18, 2025

  • 0 min

Share

Outcomes of Treatment and Factors Influencing Prognosis in Ugandan Children with Acute Myeloid Leukaemia

Overview

Expand on specific challenges faced in Uganda beyond high mortality rates and limited access.

Background

Incorporate specific statistics or studies to substantiate claims about morbidity and mortality rates.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

  • Survival rates for paediatric AML in low-income countries remain below 40%.
  • Late presentation and lack of standardized treatment protocols significantly impact outcomes.
  • Comorbidities, such as malnutrition, are prevalent and exacerbate treatment-related morbidity.
  • Prognostic factors include genetic abnormalities and achievement of minimal residual disease negativity.
  • Geographic and socioeconomic disparities affect treatment outcomes and access to care.

Clinical Implications

Detail actionable steps for healthcare providers to implement early diagnosis and standardized protocols.

Conclusion

Improving treatment outcomes for paediatric AML in Uganda requires a multifaceted approach that includes better access to care, standardized protocols, and addressing the unique challenges faced in low-income settings.

Related Resources & Content

  1. Bone Marrow Transplantation, 2021 -- Factors Influencing Outcomes Following Allogeneic Stem Cell Transplantation in Patients with Advanced Chronic Myeloid Leukemia
  2. Blood Cancer Journal, 2023 -- Predictors of Relapse in Adults with Acute Myeloid Leukemia: Factors Unrelated to Time
  3. Bone Marrow Transplantation, 2024 -- Effects of Bone Marrow Fibrosis on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Patients with Acute Myeloid Leukemia
  4. Blood Cancer Journal, 2016 -- Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life
  5. ASH, 2024 -- A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
  6. WHO Global Initiative for Childhood Cancer
  7. Paper: A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group

Original Source(s)

Outcomes of Treatment and Factors Influencing Prognosis in Ugandan Children with Acute Myeloid Leukaemia

  • by Richard Nyeko, Mariana Kruger, Nixon Niyonzima, Barnabas Atwiine, Jennifer Zungu, Joyce Balagadde Kambugu, Stijn Verhulst, Jaques van Heerden

  • December 18, 2025

Related Content

Clinicopathological and molecular characteristics of primary pulmonary choriocarcinoma: a case report and systematic review

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

  • 1 min
Metaplastic breast carcinoma with osteosarcomatous differentiation: a case report